Production, quality control, and bio-distribution studies of 159Gd-EDTMP as a palliative agent for bone pain
Keywords:
EDTMP, gadolinium, radiotherapy, boneAbstract
Introduction: Particle-emitting, bone-seeking radiopharmaceuticals have attracted the attention of the nuclear medicine community over the last three decades for the treatment of the pain of osteoblastic metastases. The objectives of this research were to produce quality-controlled 159Gd-EDTMP in order to provide a new therapeutic radiopharmaceutical for use in clinical applications.
Methods: The investigation was an experimental study in which 159Gd (T1/2=18.479 h, Eβ (max)=970.60 keV, Eγ=363.55 (11.4%) keV] was produced by thermal neutron bombardment of natural Gd2O3 at the Tehran Research Reactor (TRR) for a period of 7 d at a flux of 3–4×1013 neutrons/cm2.s. It was then quality-controlled and used to radio-label the in-house prepared ethylene diamine tetra acetic acid (EDTM).
Results: Complexation parameters were optimized to achieve maximum yields (>99%). The radiochemical purity of 159Gd-EDTMP was checked by radio thin layer chromatography RTLC. It was found to retain its stability at room temperature (>95%). Bio-distribution studies of the complexes conducted in wild rats showed significant bone uptake with rapid clearance from blood.
Conclusion: The properties of the 159Gd-EDTMP that was produced suggest then use of a new, efficient, palliative therapeutic agent for metastatic bone pain instead of some other current radiopharmaceuticals.
References
Coleman RE and Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987.
:61-6. http://dx.doi.org/10.1038/bjc.1987.13, PMid:3814476 PMCid:PMC2001575
Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer, 2002.
:584-93, http://dx.doi.org/10.1038/nrc867, PMID: 12154351.
Aldo N and Serafini, Therapy of Metastatic Bone Pain, J Nucl Med. 2001. 42:895–906, PMID: 11390554 .
Holmes, A. [153Sm]-EDTMP: a potential therapy for bone cancer. Semin Nucl Med. 1992. 22, 41-45,
http://dx.doi.org/10.1016/S0001-2998(05)80156-4, PMID: 1589805.
Farhangi, M., Holmes, R. A., Volkert, W. A., Logan, K. W and Singh., A. Samarium-153 EDTMP:
Pharmacokinetics, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone
cancer. J Nucl Med. 1992. 33, 1451-1458, PMID: 1378887 .
Maini, C. L., Bergomi, S., Romano, L and Sciuto, R. 153Sm-EDTMP for bone pain palliation in skeletal
metastases. Eur J Nucl Med Imaging. 2004. 31, 171-8, PMID: 15127241.
Turner, J. H., Claringbold, P. G., Hetherington, E. L., Sorby, P., and Martindale, A. A. A phase I study of Sm- 153 ethylenediamine-tetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol.
7, 1926-31, PMID: 2585026 .
Goeckeler, W. F., Edwards, B., Volkert, W. A., Holmes, R. A., Simon, and J., Wilson D.: Skeletal localization
of Sm-153 chelates: potential therapeutic bone agents. J Nucl Med. 1987. 28, 495-504, PMID: 3572535.
Goeckeler, W. F., Troutner, D. E., Volkert, W. A., Edwards, B., Simon, J and Wilson, D.: 153Sm
radiotherapeutic bone agents. Nucl Med Biol. 1986. 13, 479-482, PMID: 3793505.
Singh, A., Holmes, R. A., Farhangi, M., Volkert, W. A., Williams, A., Stringham, L. M., Ketring, A. R.: Human
pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med (1989) 30, 1814-8, PMid:
Anderson, P. M., Wiseman, G. A., Dispenzieri, A., Arndt, C., Hartmann, L. C., Smithson, W. A., Mullan, B. P.,
Brulan. O. S.: High-Dose Samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of
skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002. 20, 189-196,
http://dx.doi.org/10.1200/JCO.20.1.189, PMid: 11773169.
Bahrami-Samani, A., Ghannadi-Maragheh, M., Jalilian, A.R., Meftahi, M., Shirvani-Arani, S., Moradkhani, S.
Production, Quality Control and Biological Evaluation of 153Sm-EDTMP in Wild-Type Rodents. Iran J Nucl
Med .2009. 17, 12-19, PMCID: PMC3700048.
Ando, A., Ando, I., Tonami, N., Kinuya, S., Kazuma, K., Kataiwa, A., Nakagawa, M. and Fujita N. 177Lu- EDTMP: a potential therapeutic bone agent. Nucl Med Commun. 1998. 19, 587-91, PMID:10234664.
Sola, G. A. R., Arguelles, M. G., Bottazzini, D. L., Furnari, J. C., Parada, I. G., Rojo, A and Ruiz, H. V.
Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution and preclinical studies. Radiochim
Acta . 2000. 88, 157-161, http://dx.doi.org/10.1524/ract.2000.88.3-4.157.
Chakraborty, S., Das, T., Unni, P. R., Sarma, H. D., Samuel, G., Banerjee, S., Venkatesh, M., Ramamoorthy, N
and Pillai, M. R.A.177Lu-labeled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med
Commun. 2002. 23, 67-74, http://dx.doi.org/10.1097/00006231-200201000-00011, PMid: 11748440.
Das, T., Chakraborty, S., Unni, P. R., Banerjee, S., Samuel, G., Sarma, H. D., Venkatesh, M., Pillai, M.R.A.
Lu labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot. 2002.
, 177, http://dx.doi.org/10.1016/S0969-8043(02)00104-5, PMID: 12150276
Das, T., Chakraborty, S., Sarma, H. D., Banerjee, S.: 177Lu-DOTMP: a viable agent for palliative radiotherapy
of painful bone metastasis. Radiochim Acta. 2008. 96, 55. http://dx.doi.org/10.1524/ract.2008.1464.
Sudipta Chakraborty, Tapas Das, Sharmila Banerjee, Lajos Balogh, Pradip R. Chaudhari, Haladhar D. Sarma,
András Polyák, Domokos Máthé, Meera Venkatesh, Gyõzõ Janoki, and Maroor R.A. Pillai. Cancer Biotherapy
& Radiopharmaceuticals. April. 2008. 23(2): 202-213, http://dx.doi.org/10.1089/cbr.2007.374.
Moralles M, Pascholati PR, Vanin VR, Helene O. 1995. Decay of 159Gd. Appl Rad Isot 46:133–138,
http://dx.doi.org/10.1016/0969-8043(94)00101-5.
Neves M, Kling A, Oliveira A Radionuclides used for therapy and suggestion for new candidates. J Radioanal
Nucl Chem. 2005. 266:377–384, http://dx.doi.org/10.1007/s10967-005-0920-5.
Goorley T, Nikjoo H (2000) Electron and photon spectra for three gadolinium-based cancer therapy approaches.
Radiat Res 154:556–563, http://dx.doi.org/10.1667/0033-7587(2000)154[0556:EAPSFT]2.0.CO;2, PMID:
Daniel Crı´stian Ferreira Soares, Maria A ˆ ngela de Barros Correia Menezes, Raquel Gouveˆa dos Santos,
Gilson Andrade Ramaldes 159Gd: preparation and preliminary evaluation as a potential antitumoral radionuclide,
J Radioanal Nucl Chem. 2010. 284:315–320, http://dx.doi.org/10.1007/s10967-010-0486-8.
G J Beyer, R Offord, G Künzi, Y Aleksandrova, U Ravn, S Jahn, J Barker, O Tengblad, M Lindroos, The
influence of EDTMP-concentration on the biodistribution of radio-lanthanides and 225Ac in tumor-bearing mice.
Nucl Med Biol. 1997. Jul ;24 (5):367-72, http://dx.doi.org/10.1016/S0969-8051(97)80001-7, PMID:9290069.
Moedritzer, K., Irani, R. R.: Direct synthesis of α-aminomethyl phosphonic acid: Mannich type reactions with
o- phosphorus acid. J Org Chem. 1996. 31, 1603-1607. http://dx.doi.org/10.1021/jo01343a067.
Shirvani-Arani, S. Bahrami-Samani, A. Meftahi, M.. Jalilian A. R and Ghannadi-Maragheh, M. Production,
quality control and biodistribution studies of thulium-170-labeled ethylenediamine (tetramethylene
phosphonicacid), Radiochim. Acta. 2013. 101, 37–43, http://dx.doi.org/10.1524/ract.2013.1999.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
